Sales reps have been pounding doctors’ doors on behalf of Merck and Schering-Plough’s beleaguered cholesterol drug Vytorin, but their pleas aren’t getting them very far.
It’s been two months since the results of the controversial Enhance trial suggested Vytorin was no better than a cheap generic at slowing the progression of cardiovascular disease. The hullabaloo appears [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment